[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-stroke-cognitive-impairment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-stroke-cognitive-impairment":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,46,71,104,128,154],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631714","tele-rehabilitation-vs-conventional-rehabilitation-for-cognitive-improvement-in-stroke-survivors-100631714",false,"NCT07504276","Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors.","Comparison Of Tele-Rehabilitation Versus Conventional Rehabilitation To Improve Cognition Among Stroke Survivor.","Inclusion Criteria:\n\n* Adults with age 50-80\n* Diagnosed with ischemic or hemorrhagic stroke within subacute to chronic phase.\n* Moca Score 10-25 score atleast\n* For tele-rehab must accessible to a digital device.\n\nExclusion Criteria:\n\n* History of neurodegenerative disorder e.g Alzheimer's Disease and Parkinson's Disease\n* Severe Cognitive Impairment\n* Lack of access to or inability to use a digital device","ALL","50 Years","80 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to:\n\n* Compare tele-rehabilitation and conventional rehabilitation for cognitive improvement after stroke.\n* Evaluate changes in cognitive function using standardized assessment tools.\n* Determine whether tele-rehabilitation is as effective as conventional therapy.\n* Improve evidence-based rehabilitation strategies for stroke survivors.",[27,28,29],"Stroke","Cognitive Impairment","Post-Stroke Cognitive Impairment",[31,32],"Tele-rehabilitation","Conventional Rehabilitation","RECRUITING","2026-04-02",{"date":36,"type":37},"2026-04-03","ACTUAL",{"date":39,"type":37},"2026-03-31",{"date":41,"type":21},"2026-08-15",{"name":43,"class":44},"Riphah International University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100625521","key-technical-research-on-the-treatment-of-post-stroke-cognitive-impairment-with-brain-electric-field-therapy-based-on-acupoint-regulation-100625521","NCT07423715","Key Technical Research on the Treatment of Post-stroke Cognitive Impairment With Brain Electric Field Therapy Based on Acupoint Regulation","Inclusion Criteria:\n\n1. Meets diagnostic criteria for Vascular Cognitive Impairment (VCI) per the 2024 Chinese VCI guidelines.\n2. Meets TCM diagnostic criteria per the 2024 Vascular Mild Cognitive Impairment guidelines.\n3. Cognitive scores: MMSE 12-24 and MoCA \\\u003C24; NIHSS ≤8; AD-8 \\\u003C2.\n4. Age 35-80 years.\n5. Basic communication ability (Mandarin) and has a stable caregiver.\n6. Provides written informed consent.\n\nExclusion Criteria:\n\n1. Severe chronic systemic diseases (e.g., cardiac, hepatic, renal, hematologic) or unstable cardiovascular\u002Fcerebrovascular disease.\n2. Local skin conditions (e.g., herpes, ulceration, keloid) contraindicating acupuncture.\n3. Contraindications for repeated MRI (e.g., claustrophobia, post-aneurysm embolization).\n4. Pre-existing cognitive impairment or other major uncontrolled neurological\u002Fpsychiatric disorders.\n5. Deemed unsuitable for the study by investigators.\n6. Participation in another clinical trial within the past 3 months.","35 Years",{"count":54,"type":21},110,[24],"This clinical study investigates whether electroacupuncture can improve thinking and memory in people with cognitive problems after a stroke (Post-Stroke Cognitive Impairment, or PSCI).\n\nParticipants will be randomly assigned to one of two groups: one group will receive real electroacupuncture, while the other will receive a sham treatment . Both groups will also receive standard medical care.The main goal is to see if the real electroacupuncture leads to greater improvement in cognitive function tests over 6 months compared to the sham treatment. The study will also use brain scans (MRI) and other assessments to understand how the treatment might work.",[29],[29,59,60],"Acupoint Regulation","Brain Electric Field Therapy","NOT_YET_RECRUITING","2026-02-14",{"date":64,"type":37},"2026-02-20",{"date":66,"type":21},"2026-02-10",{"date":68,"type":21},"2027-12-31",{"name":70,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":88,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100615254","tridimensional-robotic-assessment-of-neglect-in-brain-injured-patients-100615254","NCT07290218","Tridimensional Robotic Assessment of Neglect in Brain Injured Patients","NEGLECTARM3D","Inclusion Criteria:\n\n* Age \\> 18 years;\n* Diagnosis of ischemic or hemorrhagic stroke;\n* Diagnosis of Unilateral Spatial Neglect (assessed by The Hearts Test, Oxford Cognitive Screen, cut-off ± 2);\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* Presence of language deficits (inability to complete the OCS test);\n* Presence of cognitive decline prior to the stroke event;\n* Presence of severe visual and\u002For hearing impairments;\n* Language barriers;\n* Orthopedic, neurological, or psychiatric conditions that could interfere with the study or with the assessment of motor and cognitive function;\n* Uncontrolled epilepsy despite antiepileptic treatment;\n* Behavioral disorders that may interfere with study participation;\n* Presence of medical devices whose functioning could be compromised (e.g., pacemaker, etc.);\n* Object-centered neglect (assessed by the OCS Hearts Test; object asymmetry ± 2).","18 Years",{"count":80,"type":21},15,"OBSERVATIONAL","The goal of this clinical trial is to assess the usability and feasibility of a robotic and virtual reality-based system called NeglectARm 3D for the three-dimensional assessment of unilateral spatial neglect (USN) in patients with brain injury due to ischemic or hemorrhagic stroke.\n\nThe main questions it aims to answer are:\n\n* Is the NeglectARm 3D system usable and feasible for patients with USN?\n* Do the robotic measurements show preliminary reliability and validity compared with conventional clinical neglect assessments (e.g., BIT, CBS)?\n\nParticipants will:\n\n* Perform two assessment sessions, three weeks apart (T0 and T1);\n* Interact with the NeglectARm 3D system using a robotic end-effector and a VR headset to reach sequentially presented targets in a 3D virtual space;\n* Receive robotic assistance if targets are not reached, allowing the system to record trajectories, spatial positions, and assistance applied;\n* Complete standard clinical neglect tests to enable comparison between robotic and conventional measures.\n\nThis study aims to develop a repeatable, standardized, and objective tool for the assessment of USN in patients with brain injury, potentially improving evaluation of depth perception and spatial attention deficits.",[84,85,27,86,87],"Neglect","Brain Injured Patients","Unilateral Spatial Neglect (USN)","Post-stroke Cognitive Impairment",[84,89,90,91,92,93],"Brain injured patients","Tridimensional robotic assessment","Force-sensitive robot system","Virtual reality (VR) headset","Collaborative robotic system","2025-12-04",{"date":96,"type":37},"2025-12-18",{"date":98,"type":21},"2026-01-01",{"date":100,"type":21},"2026-11-30",{"name":102,"class":44},"Fondazione Don Carlo Gnocchi Onlus",3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":18,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100540314","phase-2-edaravone-dexborneol-sublingual-tablet-for-the-psci-in-acute-ischemic-stroke-patients-100540314","NCT06315231","Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients","Efficacy and Safety of Edaravone Dexborneol Sublingual Tablet for Post-stroke Cognitive Impairment in Patients With Acute Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled, Exploratory Phase II Clinical Trial.","Inclusion Criteria:\n\n1. Age ≥ 40 years and ≤ 80 years, male or female.\n2. Diagnosed as ischemic stroke, no significant pre-stroke functional disability (mRS score ≤ 1prior to stroke onset).\n3. The National Institutes of Stroke Scale score ≤ 20 points.\n4. Time from onset to obtained informed consent form is within 7 days (including 7 days).\n5. Presence of cognitive dysfunction at screening, i.e., MoCA scale score \\\u003C 22.\n6. Patients with good cognitive function prior to stroke, without significant cognitive dysfunction and dementia.\n7. Education level: primary school or above, and can complete the cognitive function test required per investigator's judgement.\n8. female subjects of childbearing potential and male subjects whose female partners are of childbearing potential must be willing to and use contraception during the study treatment and within 30 days after the last dose of study drug and have no plans to donate sperm or eggs; female subjects of childbearing potential will have a negative pregnancy test;\n9. obtain voluntary signed informed consent from the patient or his\u002Fher legal representative approved by the Ethics Committee.\n\nExclusion Criteria:\n\n1. Presence of intracranial hemorrhagic disease confirmed by brain imaging.\n2. Severe disturbance of consciousness: NIHSS 1a level of consciousness item score \\> 1 point.\n3. Transient ischemic attack (TIA).\n4. Systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 120 mmHg after blood pressure control.\n5. Poorly controlled diabetes (fasting blood glucose \\>10mmol\u002FL and\u002For HbA1c\\>8%).\n6. Patients with contraindications to MRI imaging.\n7. For subjects who are scheduled to undergo EEG examination, Patients with contraindications for EEG examination.\n8. Presence of cognitive dysfunction prior to stroke assessed by informants, that is, the average score of Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE, 16-item version) during the screening period was ≥ 3.19 and the total score was ≥ 51.\n9. Patients who have been diagnosed with severe mental disorders prior to stroke.\n10. Severe limb hemiplegia and aphasia and significantly affect cognitive function assessment.\n11. Patients have received the cognitive enhancers and other anti-dementia drugs within 1 month before the screening period, including but not limited to cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and non-competitive N-methyl-D-aspartate (NMDA) receptor antagonists (memantine) and other drugs (such as mannitol sodium capsules, Ginkgo Biloba Extract Injection, Compound Ginkgo Biloba Tablets, oxiracetam, aniracetam, piracetam，nicergoline, Lecanemab, Donanemab, Aducanumab, etc. ).\n12. Have been diagnosed with severe active liver disease, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc.; or ALT or AST \\> 2.0 × ULN.\n13. Has been diagnosed with severe active kidney disease, renal insufficiency; or serum creatinine \\> 1.5 × ULN.\n14. Thrombectomy or interventional therapy has been applied or planned after this episode.\n15. History of malignancy; except for subjects with non-melanoma skin cancer (NMSC) that has been successfully treated and limited cervical cancer in situ. Subjects with a diagnosis of malignancy after enrollment may continue to participate in the study or not at the discretion of the investigator and at the discretion of the subject;\n16. Suffering from a severe systemic disease with an expected survival period of \\\u003C1 year;\n17. hypersensitivity to dextran camphene, natural ice chips or edaravone or excipients (mannitol, copovidone, microcrystalline cellulose, cross-linked povidone, silicon dioxide, magnesium stearate);\n18. pregnancy, lactation, and patients planning pregnancy;\n19. history of major surgery within 4 weeks prior to enrollment;\n20. participation in another clinical study within 30 days prior to randomization, or ongoing participation in another clinical study;\n21. in the opinion of the investigator, not suitable for participation in this clinical study.","40 Years",{"count":113,"type":21},226,[115],"PHASE2","This is a multicenter, randomized, double-blind, placebo-controlled, exploratory Phase II clinical trial.\n\nThe goal of this clinical trial is to assess the safety and efficacy of edaravone dexborneol sublingual tablets for post-stroke cognitive impairment in patients with acute ischemic stroke.\n\nParticipants will be required to receive 24 weeks treatment of edaravone dexborneol sublingual tablets or placebo during this study. The safety and efficacy endpoints will be compared in the patients with edaravone dexborneol sublingual tablets or placebo.",[87],"2025-09-01",{"date":120,"type":37},"2025-09-03",{"date":122,"type":37},"2024-04-08",{"date":124,"type":21},"2026-12-30",{"name":126,"class":44},"Simcere Pharmaceutical Co., Ltd",21,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":78,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":45},"100540416","hope-from-the-cerebellum-tms-induced-cognitive-recovery-after-stroke-100540416","NCT06316557","HOPE From the Cerebellum: TMS-Induced Cognitive Recovery After Stroke","HOPE","Key inclusion criteria:\n\n(1)ischemic stroke, with an initial incident occurring within 2 weeks;(2)MoCA\\\u003C26;\n\nKey exclusion criteria:\n\n(1)Cerebral hemorrhage or subarachnoid hemorrhage;(2)A pre-existing history of epilepsy;",{"count":136,"type":21},70,[24],"The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.",[87,140],"Ischemic Stroke",[87,142,143,144],"Repetitive transcranial magnetic stimulation","High-frequency","Cerebellar","2025-06-30",{"date":147,"type":37},"2025-07-02",{"date":149,"type":37},"2025-01-01",{"date":151,"type":21},"2027-04-01",{"name":153,"class":44},"Zi-Xiao Li",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":161,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100551304","local-opera-viewing-combined-medical-gymnastics-for-elderly-psci-100551304","NCT06458348","Local Opera Viewing Combined Medical Gymnastics for Elderly PSCI","Construction and Empirical Study of Local Opera Appreciation Combined With Medical Gymnastics Training Program for Elderly Patients With Post-stroke Cognitive Impairment","Inclusion Criteria:\n\nStroke patients who were hospitalized in the Department of Neurology of Zhangzhou Hospital and met the PSCI diagnostic criteria of the Expert Consensus on the Prevention and Treatment of Cognitive Impairment after Stroke in China were the subjects of the study. ① Stroke patients confirmed by neuroimaging, onset time within 1 week; (2) Cognitive impairment occurs after stroke events; ③ The scores of the simple mental state examination scale were points in the illiterate group, points in the primary school group, points in the secondary school group, and points in the college group; ④ can maintain independent sitting position ≥30 min; ⑤ Age ≥60 years old; ⑥ Volunteer to join the study and receive intervention treatment.\n\nExclusion Criteria:\n\n* Other causes affect or lead to cognitive impairment, such as consciousness disorder, malignant tumor, severe liver and kidney insufficiency; ② There are serious cardiopulmonary and other systemic diseases; Visual or hearing impairment; ④ have emotional behavior abnormalities and mental illness (including depression); ⑤ A history of alcohol or drug abuse","60 Years","100 Years",{"count":164,"type":21},160,[24],"local opera viewing combined medical gymnastics for elderly PSCI",[87],"2024-06-09",{"date":170,"type":37},"2024-06-13",{"date":172,"type":21},"2024-07-01",{"date":174,"type":21},"2026-08-31",{"name":176,"class":44},"Zhangzhou Municipal Hospital"]